8gaming slot
Macklin Celebrini might be the best under-20 hockey player from North Vancouver in the NHL right now. Now, that may sound so oddly specific that it's actually a backhanded compliment, like Flight of the Conchords singing about " The most beautiful girl (in the room) ," but it's actually high praise because his competition is Connor Bedard. Celebrini and Bedard were both picked first overall in back-to-back years and Celebrini is arguably having a better rookie season than Bedard did last year. It's far too early to declare one the winner in what isn't really a competition — at least, not until they face each other in the playoffs at some point in the future — but Celebrini has been fantastic for the San Jose Sharks. With 11 goals and 23 points in 24 games, Celebrini is leading the Sharks in points per game, and he's been particularly good recently. He has three goals and eight points in his last six games, though the team around him is still not great — the Sharks lost five of those six games. Despite Celebrini's excellence, the Sharks are dead last in the Pacific Division with an 11-19-6 record. On Monday night, Celebrini will play his first NHL game at Rogers Arena, though it's far from his first time in the arena. Celebrini grew up as a dyed-in-the-wool Canucks fan and his most recent trip to Rogers Arena was for Game 7 against the Edmonton Oilers, where he cheered on the Canucks just before he was drafted by the Sharks. He'll be looking for the same result as that game as he faces his hometown team for the first time. Celebrini will be facing a Canucks team that is reeling. They've lost three straight games and six of their last eight, though they took three of those losses to overtime to earn a single point. The Canucks' record as a whole would look a lot better if they had managed to win a few more of their overtime games. The Canucks have taken ten games to overtime this season and won just three of them. Despite that, the Canucks' 16-10-7 record is still good enough to have them fourth in the Pacific Division and in the first wild card spot in the Western Conference by points percentage. If the Canucks can sort out their game and whatever off-ice issues may or may not exist, they're still in a good position to make some noise in the back half of the season. Nils Höglander is expected to get back into the lineup after he was a healthy scratch for two games. He practice on a top-six line alongside Elias Pettersson and Jake DeBrusk on Sunday. Hopefully, the two-game break was what Höglander needed to find his game again, as he had gone 21 games without a point and 26 games without a goal before he was scratched. Linus Karlsson will come out of the lineup for Höglander, which makes a lot of sense. Karlsson simply did not look like an NHLer in his two games and the lack of footspeed was very apparent. As good as Karlsson has been in the AHL, he just hasn't been able to translate his game to the NHL level. The Canucks' starting goaltender is expected to be Thatcher Demko, who has never lost to the San Jose Sharks in 11 starts. He has an 11-0-0 record against the Sharks with a .925 save percentage in his career. While Celebrini is the star, the Sharks are getting decent offensive contributions from a few other forwards. Former Canuck Tyler Toffoli leads the Sharks in goals with 13, while Mikael Granlund leads the team in points with 32 in 34 games. That trio gives the Sharks a pretty dangerous top line; shutting them down will be a priority for the Canucks. Here are the projected lines for the Sharks, courtesy of beat reporter Curtis Pashelka : Mikael Granlund - Macklin Celebrini - Tyler Toffoli William Eklund - Alexander Wennberg - Will Smith Nikolai Kovalenko - Luke Kunin - Fabian Zetterlund Barclay Goodrow - Nico Sturm - Ty Dellandrea Henry Thrun - Cody Ceci Mario Ferraro - Timothy Liljegren Shakir Mukhamadullin - Jan Rutta Yaroslav Askarov Alexandar Georgiev The Sharks will be without the services of top defenceman Jake Walman, who has 25 points in 31 games this season. Walman is out day-to-day with a lower-body injury. The Sharks' starting goaltender is expected to be Yaroslav Askarov. The 22-year-old netminder has been outstanding in his three starts this season, even as the team in front of him hasn't provided a lot of support. He has a .928 save percentage and earned the Sharks at least a point in all three games with a 1-0-2 record.The rivalry between two of the world's richest men, Elon Musk and Jeff Bezos, has once again become a topic of discussion. Musk accused Bezos of having urged the public to sell Tesla and SpaceX stocks before the critical U.S. presidential election. In a post on X (formerly Twitter), Musk also alleged that Bezos had said Trump was going to lose. In an unusual statement, Bezos responded by outright denying the claims. Musk's Accusation Elon Musk, a prominent supporter of Donald Trump during the election, accused Jeff Bezos of telling people that Trump would certainly lose. According to Musk, the panic created from this statement might have caused some people to sell their Tesla and SpaceX stocks out of a growing fear that if Trump lost, there might be market repercussions. Musk tweeted that someone had told him this at Mar-a-Lago, Trump's resort in Florida. Bezos Denies Claims Jeff Bezos, hardly ever present on social media, came back with a short but to-the-point denial of Musk's claims. In his first post since November 6, Bezos stated: “Nope. 100% not true.” Musk later pressed a laughing emoji and said: “Well, then, I stand corrected.” What It Looks Like Musk is said to have spent over $130 million on Trump's reelection campaign and has had a close connection with the former president. There have been a series of controversies over his association with Trump, fearing that it may sting Tesla and SpaceX stocks during political turmoil moments. It seems that Musk and Bezos fought an antagonistic battle, and the companies Tesla and Amazon are always embroiled in the technological and innovation wars with one another. In this case, for now, the matter appears to be settled, illustrating the growing public nature of disputes between billionaire titans. Get Latest News Live on Times Now along with Breaking News and Top Headlines from Technology Science and around the world.
France's second woman premier makes surprise frontline return
Dear Eric: When my only son and his wife got married and had kids, I was informed that Christmas Day would just be for them to celebrate. I said OK. For decades, I have given my son and his family (wife and two kids) really nice gifts for Christmas. We are talking about hundreds of dollars. For a while, I would receive a small gift, such as a bottle of homemade vanilla, a rose-scented tin of salve made by a friend of the wife or a coffee cup or some such as a gift from the family. Same with my birthday. I have never received a gift from the grandkids. Last year, I let them know I would no longer be “exchanging” gifts with the parents but gifts to the grandkids (who are now teenagers with jobs) will continue. That year, I got them electronics and hoodies. I got nothing from anyone. Not even an acknowledgement from the kids. I have always had to deliver the gifts or call to see if they received them. This year, it is only going to be a Christmas card. Am I being overly sensitive? — Empty Stocking People are also reading... Dear Stocking: No, you are not being overly sensitive. Every family has their own traditions and needs. And no one is obligated to give — or accept — a gift. But it sure does make me sad that your desire to make this holiday special isn’t being reciprocated. Part of it may be a misalignment of expectations. You’ve given generously, into the hundreds of dollars. I’m curious if your son and daughter-in-law have different values or wants around gifting that are either not being expressed or not being heard. They should tell you clearly. Similarly, when you decided to stop giving gifts to the adults, I’m curious if your expectations were that your son would realize that you weren’t getting what you wanted and make a change. It’s worth talking it through a little more but try to focus on the want behind the want. I suspect that what you’re craving is connection — and perhaps an invitation to the family Christmas. It makes sense that you’d try to show your love from a distance through gift-giving and it makes sense that it would hurt not to have it reciprocated. But perhaps the tradition of gifts is getting in the way on both sides. If you’d like to be invited or would like to find an alternate way of celebrating and being together, that’s a great gift to ask for. Dear Eric: I was riding my bicycle when, unbeknownst to me, my wallet fell out of my pocket. My driver’s license, credit cards and about $200 in cash were in the wallet. Later that day I received a telephone call from a cyclist who found my wallet on his ride and told me that I could come over to pick it up. What, if any, reward would be appropriate? I gave a $30 bottle of wine. — Grateful Cyclist Dear Cyclist: How lucky that your path crossed with such a good fellow citizen! Etiquette experts agree that the amount of a reward in situations like this is really up to you. So, the bottle of wine you gave works. My only suggestion, however, would be that, if this ever happens again (fingers crossed your wallet stays in your pocket from now on), you check with the recipient to make sure that they drink wine. It’s the thought that counts, but you don’t want your grateful efforts to put someone else in an uncomfortable or dangerous situation. Send questions to R. Eric Thomas at eric@askingeric.com . Be the first to know Get local news delivered to your inbox!Fresno State QB Mikey Keene transferring to Michigan
William Blair reissued their outperform rating on shares of Larimar Therapeutics ( NASDAQ:LRMR – Free Report ) in a report released on Tuesday morning, RTT News reports. Several other equities analysts have also commented on the company. Baird R W raised Larimar Therapeutics to a “strong-buy” rating in a research report on Wednesday, September 4th. Robert W. Baird began coverage on Larimar Therapeutics in a report on Wednesday, September 4th. They issued an “outperform” rating and a $16.00 price target for the company. Oppenheimer began coverage on Larimar Therapeutics in a research note on Wednesday, October 16th. They set an “outperform” rating and a $26.00 price objective for the company. HC Wainwright restated a “buy” rating and set a $15.00 price objective on shares of Larimar Therapeutics in a research note on Monday, November 18th. Finally, Wedbush assumed coverage on Larimar Therapeutics in a research note on Thursday, October 3rd. They issued an “outperform” rating and a $22.00 price target for the company. Ten research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, Larimar Therapeutics has a consensus rating of “Buy” and an average price target of $20.43. View Our Latest Research Report on LRMR Larimar Therapeutics Stock Up 0.5 % Larimar Therapeutics ( NASDAQ:LRMR – Get Free Report ) last issued its quarterly earnings results on Wednesday, October 30th. The company reported ($0.24) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.37) by $0.13. During the same period last year, the business earned ($0.21) earnings per share. As a group, equities analysts expect that Larimar Therapeutics will post -1.16 EPS for the current fiscal year. Institutional Inflows and Outflows Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. RA Capital Management L.P. acquired a new stake in shares of Larimar Therapeutics in the first quarter valued at about $45,884,000. Janus Henderson Group PLC grew its position in shares of Larimar Therapeutics by 52.2% in the first quarter. Janus Henderson Group PLC now owns 4,020,965 shares of the company’s stock valued at $30,459,000 after purchasing an additional 1,379,900 shares during the last quarter. Vanguard Group Inc. boosted its stake in shares of Larimar Therapeutics by 62.7% in the first quarter. Vanguard Group Inc. now owns 2,367,701 shares of the company’s stock valued at $17,971,000 after buying an additional 912,458 shares during the period. Millennium Management LLC boosted its stake in shares of Larimar Therapeutics by 30.2% in the second quarter. Millennium Management LLC now owns 1,018,135 shares of the company’s stock valued at $7,381,000 after buying an additional 235,865 shares during the period. Finally, Driehaus Capital Management LLC lifted its stake in Larimar Therapeutics by 20.8% during the second quarter. Driehaus Capital Management LLC now owns 1,314,106 shares of the company’s stock worth $9,527,000 after purchasing an additional 225,879 shares during the last quarter. 91.92% of the stock is currently owned by institutional investors. Larimar Therapeutics Company Profile ( Get Free Report ) Larimar Therapeutics, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease. Read More Receive News & Ratings for Larimar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Larimar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter .
Calzada TD to Alexander sends Incarnate Word to FCS quarterfinal with win over Villanova
BlackBerry (NYSE:BB) Cut to “Sell” at StockNews.com
December 6 saw 7,437 shares trade on the Bermuda Stock Exchange, valued at $270,913.00 BD. 7,437 shares were traded by Bank of N.T. Butterfield Ltd, closing down 2.0% at $36.00 per share. The BSX finished at 2,487.13, down 1.59% on the day. There were 0 advances, 1 decline, and 52 remained unchanged. The full report for the day is available , and the full report for the week is available . : ,Phase 3 Study Results Demonstrated Three Year, Disease-Free Survival of 96% THOUSAND OAKS, Calif. , Dec. 7, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced new data demonstrating that adding BLINCYTO ® (blinatumomab) to chemotherapy significantly improves disease-free survival (DFS) in newly diagnosed pediatric patients with National Cancer Institute (NCI) standard risk (SR) B-cell acute lymphoblastic leukemia (B-ALL) of average or higher risk of relapse. The data are from a Phase 3 study (AALL1731) conducted by the Children's Oncology Group. The results were simultaneously published in the New England Journal of Medicine and will be presented during the plenary session on Sunday, Dec. 8 , at 2 p.m. PT at the 66 th American Society of Hematology (ASH) Annual Meeting & Exposition in San Diego . "Over the last decade, BLINCYTO has reshaped the treatment landscape for B-ALL, offering a critical lifeline for thousands of adult and pediatric patients," said Jay Bradner , M.D., executive vice president of Research and Development and chief scientific officer at Amgen. "These powerful new data leave us little doubt about the profound impact of this medicine for a large number of children affected by this disease. We are grateful to the Children's Oncology Group, along with the patients, families and clinical teams, for their dedication and partnership in advancing this critical study to improve the lives of children with cancer." Based on the results of the first pre-specified interim analysis for efficacy, the study met its primary endpoint of DFS and study randomization was terminated early based on the recommendation from the data and safety monitoring committee due to the benefit observed in the BLINCYTO arm compared to the chemotherapy-only arm. Overall, the 3-year DFS was 96.0% for patients treated with chemotherapy plus BLINCYTO compared to 87.9% for those treated with only chemotherapy. The hazard ratio (HR) was 0.39 [95% confidence interval (CI) 0.24-0.64], indicating a 61% reduction in the risk of disease relapse, secondary malignant neoplasm or remission death with BLINCYTO. At 3 years, more patients remained alive and cancer free when treated with BLINCYTO plus chemotherapy compared to chemotherapy alone. "The AALL1731 study results are truly practice-changing, further solidifying blinatumomab's role as the standard of care for a large number of children with B-ALL," said Sumit Gupta , M.D., Ph.D., FRCPC, co-chair of the Children's Oncology Group AALL1731 study and oncologist and clinician investigator, Division of Haematology/Oncology at The Hospital for Sick Children (SickKids) and associate professor of pediatrics at the University of Toronto . "These breakthrough data showing a significant improvement in disease-free survival are poised to bring substantial clinical value to children with newly diagnosed B-ALL." The addition of BLINCYTO to chemotherapy in standard risk patients resulted in outcomes similar to those previously achieved in only the most favorable pediatric risk subsets. Among SR-Average patients, 3-year DFS was 97.5% for patients treated with BLINCYTO compared to 90.2% for those treated with only chemotherapy (HR 0.33, CI 0.15-0.69). For SR-High patients, 3-year DFS was 94.1% for those treated with BLINCYTO compared to 84.8% for those treated with only chemotherapy (HR 0.45, 95% CI 0.24-0.85). "Relapsed ALL remains a major cause of pediatric cancer mortality, with nearly half of the relapses occurring in children with standard-risk B-ALL," said Rachel E. Rau , M.D., co-chair of the Children's Oncology Group AALL1731 study, pediatric hematologist-oncologist at Seattle Children's Hospital and associate professor of pediatrics at the University of Washington . "These findings underscore the progress made with blinatumomab in preventing relapse and support its role as a critical addition to current therapeutic strategies." Safety results are consistent with the known safety profile of BLINCYTO. BLINCYTO has demonstrated a positive balance of benefits and risks, with only 0.3% of first courses associated with Grade 3+ cytokine release syndrome (CRS) and 0.7% with seizures. A higher risk of infections was observed in the BLINCYTO arm. These results provide the first evidence supporting BLINCYTO for use in the consolidation phase in newly diagnosed pediatric Philadelphia chromosome-negative (Ph-) B-ALL patients. This groundbreaking first-in-class Bispecific T-cell Engager (BiTE ® ) therapy is now backed by additional evidence reinforcing its role in redefining a standard of care for both adult and pediatric patients, starting from one month old, regardless of measurable residual disease (MRD) status. The findings further establish BLINCYTO as a versatile first-line consolidation therapy across all ages and treatment backbones. The NCI's Cancer Therapy Evaluation Program (CTEP), which sponsored the study will share data with the U.S. Food and Drug Administration as part of their ongoing communications relating to the trial. About The Children's Oncology Group The Children's Oncology Group (childrensoncologygroup.org), a member of the NCI National Clinical Trials Network (NCTN), is the world's largest organization devoted exclusively to childhood and adolescent cancer research. The Children's Oncology Group unites over 10,000 experts in childhood cancer at more than 200 leading children's hospitals, universities and cancer centers across North America , Australia , New Zealand and Saudi Arabia in the fight against childhood cancer. Today, more than 80% of the 15,000 children and adolescents diagnosed with cancer each year in the United States are cared for at Children's Oncology Group member institutions. Research performed by Children's Oncology Group institutions over the past 50 years has transformed childhood cancer from a virtually incurable disease to one with a combined 5-year survival rate of 86%. The Children's Oncology Group's mission is to improve the cure rate and outcomes for all children with cancer. About AALL1731 (NCT03914625) The AALL1731 study was a Phase 3 randomized trial to determine if two non-sequential cycles of BLINCYTO added to chemotherapy improved disease-free survival (DFS) in children with newly diagnosed pediatric National Cancer Institute (NCI) standard risk (SR) B-cell acute lymphoblastic leukemia (B-ALL). The study enrolled 4,264 newly diagnosed NCI SR B-ALL patients, of whom 2,334 were risk stratified at the end of induction therapy as either SR-Average or SR-High. At the first planned interim efficacy analysis (data cutoff June 30, 2024 ), 1,440 of the eligible and evaluable patients had been randomized. The AALL1731 study was designed and conducted independently from industry. The Cancer Therapy Evaluation Program (CTEP) of the NCI sponsored the trial and provided funding to the Children's Oncology Group to conduct the study. NCI is part of the National Institutes of Health (NIH). In addition, Amgen provided BLINCYTO and support through an NCI Cooperative Research and Development Agreement. About Acute Lymphoblastic Leukemia (ALL) ALL, also known as acute lymphoblastic leukemia, is a fast-growing type of blood cancer that develops in the bone marrow and can sometimes spread to other parts of the body, including the lymph nodes, liver, spleen and central nervous system. ALL is a rare disease, with an estimated 6,550 new cases, affecting both children and adults, diagnosed in the U.S. in 2024. 1 B-ALL begins in immature cells that would normally develop into B-cell lymphocytes, which are white blood cells that grow in bone marrow. 2,3 B-ALL is the most common type of ALL, constituting approximately 75% of cases in adults and approximately 88% in children, the most common cancer in children. 4,5 About BLINCYTO ® (blinatumomab) BLINCYTO is the first globally approved Bispecific T-cell Engager (BiTE ® ) immuno-oncology therapy that targets CD19 surface antigens on B cells. BiTE ® molecules fight cancer by helping the body's immune system detect and target malignant cells by engaging T cells (a type of white blood cell capable of killing other cells perceived as threats) to cancer cells. By bringing T cells near cancer cells, the T cells can inject toxins and trigger cancer cell death (apoptosis). BiTE ® immuno-oncology therapies are currently being investigated for their potential to treat a wide variety of cancers. BLINCYTO was granted Breakthrough Therapy and Priority Review designations by the U.S. FDA and is approved in the U.S. for the treatment of: In the European Union (EU), BLINCYTO is indicated as monotherapy for the treatment of: BLINCYTO ® IMPORTANT SAFETY INFORMATION WARNING: CYTOKINE RELEASE SYNDROME and NEUROLOGICAL TOXICITIES including IMMUNE EFFECTOR CELL-ASSOCIATED NEUROTOXICITY SYNDROME Contraindications BLINCYTO ® is contraindicated in patients with a known hypersensitivity to blinatumomab or to any component of the product formulation. Warnings and Precautions Adverse Reactions Dosage and Administration Guidelines INDICATIONS BLINCYTO ® (blinatumomab) is indicated for the treatment of CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL) in adult and pediatric patients one month and older with: Please see BLINCYTO ® full Prescribing Information , including BOXED WARNINGS. About Bispecific T-Cell Engager (BiTE ® ) Technology BiTE technology is a targeted immuno-oncology platform that is designed to engage a patient's own T cells to any tumor-specific antigen, activating the cytotoxic potential of T cells to eliminate detectable cancer. The BiTE immuno-oncology platform has the potential to treat different cancer types through tumor-specific antigens. The BiTE platform has a goal of leading to off-the-shelf solutions, which have the potential to make innovative T-cell treatment available to all providers when their patients need it. For more than a decade, Amgen has been advancing this innovative technology, which has demonstrated strong efficacy in hematological malignancies and now a solid tumor with the approval of IMDELLTRA. Amgen remains committed to progressing multiple BiTE molecules across a broad range of hematologic and solid tumor malignancies, paving the way for additional applications in more tumor types. Amgen is further investigating BiTE technology with the goal of enhancing patient experience and therapeutic potential. To learn more about BiTE technology, visit BiTE ® Technology 101 . About Amgen Amgen discovers, develops, manufactures and delivers innovative medicines to help millions of patients in their fight against some of the world's toughest diseases. More than 40 years ago, Amgen helped to establish the biotechnology industry and remains on the cutting-edge of innovation, using technology and human genetic data to push beyond what's known today. Amgen is advancing a broad and deep pipeline that builds on its existing portfolio of medicines to treat cancer, heart disease, osteoporosis, inflammatory diseases and rare diseases. In 2024, Amgen was named one of the "World's Most Innovative Companies" by Fast Company and one of "America's Best Large Employers" by Forbes, among other external recognitions . Amgen is one of the 30 companies that comprise the Dow Jones Industrial Average ® , and it is also part of the Nasdaq-100 Index ® , which includes the largest and most innovative non-financial companies listed on the Nasdaq Stock Market based on market capitalization. For more information, visit Amgen.com and follow Amgen on X , LinkedIn , Instagram , TikTok , YouTube and Threads . Amgen Forward-Looking Statements This news release contains forward-looking statements that are based on the current expectations and beliefs of Amgen. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including any statements on the outcome, benefits and synergies of collaborations, or potential collaborations, with any other company (including BeiGene, Ltd. or Kyowa Kirin Co., Ltd.), the performance of Otezla ® (apremilast) (including anticipated Otezla sales growth and the timing of non-GAAP EPS accretion), Amgen's acquisitions of Teneobio, Inc., ChemoCentryx, Inc., or Horizon Therapeutics plc (including the prospective performance and outlook of Horizon's business, performance and opportunities, any potential strategic benefits, synergies or opportunities expected as a result of such acquisition, and any projected impacts from the Horizon acquisition on Amgen's acquisition-related expenses going forward), as well as estimates of revenues, operating margins, capital expenditures, cash, other financial metrics, expected legal, arbitration, political, regulatory or clinical results or practices, customer and prescriber patterns or practices, reimbursement activities and outcomes, effects of pandemics or other widespread health problems on Amgen's business, outcomes, progress, and other such estimates and results. Forward-looking statements involve significant risks and uncertainties, including those discussed below and more fully described in the Securities and Exchange Commission reports filed by Amgen, including its most recent annual report on Form 10-K and any subsequent periodic reports on Form 10-Q and current reports on Form 8-K. Unless otherwise noted, Amgen is providing this information as of the date of this news release and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise. No forward-looking statement can be guaranteed and actual results may differ materially from those Amgen projects. Discovery or identification of new product candidates or development of new indications for existing products cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate or development of a new indication for an existing product will be successful and become a commercial product. Further, preclinical results do not guarantee safe and effective performance of product candidates in humans. The complexity of the human body cannot be perfectly, or sometimes, even adequately modeled by computer or cell culture systems or animal models. The length of time that it takes for Amgen to complete clinical trials and obtain regulatory approval for product marketing has in the past varied and Amgen expects similar variability in the future. Even when clinical trials are successful, regulatory authorities may question the sufficiency for approval of the trial endpoints Amgen has selected. Amgen develops product candidates internally and through licensing collaborations, partnerships and joint ventures. Product candidates that are derived from relationships may be subject to disputes between the parties or may prove to be not as effective or as safe as Amgen may have believed at the time of entering into such relationship. Also, Amgen or others could identify safety, side effects or manufacturing problems with its products, including its devices, after they are on the market. Amgen's results may be affected by its ability to successfully market both new and existing products domestically and internationally, clinical and regulatory developments involving current and future products, sales growth of recently launched products, competition from other products including biosimilars, difficulties or delays in manufacturing its products and global economic conditions. In addition, sales of Amgen's products are affected by pricing pressure, political and public scrutiny and reimbursement policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, Amgen's research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. Amgen's business may be impacted by government investigations, litigation and product liability claims. In addition, Amgen's business may be impacted by the adoption of new tax legislation or exposure to additional tax liabilities. If Amgen fails to meet the compliance obligations in the corporate integrity agreement between Amgen and the U.S. government, Amgen could become subject to significant sanctions. Further, while Amgen routinely obtains patents for its products and technology, the protection offered by its patents and patent applications may be challenged, invalidated or circumvented by its competitors, or Amgen may fail to prevail in present and future intellectual property litigation. Amgen performs a substantial amount of its commercial manufacturing activities at a few key facilities, including in Puerto Rico, and also depends on third parties for a portion of its manufacturing activities, and limits on supply may constrain sales of certain of its current products and product candidate development. An outbreak of disease or similar public health threat, such as COVID-19, and the public and governmental effort to mitigate against the spread of such disease, could have a significant adverse effect on the supply of materials for Amgen's manufacturing activities, the distribution of Amgen's products, the commercialization of Amgen's product candidates, and Amgen's clinical trial operations, and any such events may have a material adverse effect on Amgen's product development, product sales, business and results of operations. Amgen relies on collaborations with third parties for the development of some of its product candidates and for the commercialization and sales of some of its commercial products. In addition, Amgen competes with other companies with respect to many of its marketed products as well as for the discovery and development of new products. Further, some raw materials, medical devices and component parts for Amgen's products are supplied by sole third-party suppliers. Certain of Amgen's distributors, customers and payers have substantial purchasing leverage in their dealings with Amgen. The discovery of significant problems with a product similar to one of Amgen's products that implicate an entire class of products could have a material adverse effect on sales of the affected products and on its business and results of operations. Amgen's efforts to collaborate with or acquire other companies, products or technology, and to integrate the operations of companies or to support the products or technology Amgen has acquired, may not be successful. There can be no guarantee that Amgen will be able to realize any of the strategic benefits, synergies or opportunities arising from the Horizon acquisition, and such benefits, synergies or opportunities may take longer to realize than expected. Amgen may not be able to successfully integrate Horizon, and such integration may take longer, be more difficult or cost more than expected. A breakdown, cyberattack or information security breach of Amgen's information technology systems could compromise the confidentiality, integrity and availability of Amgen's systems and Amgen's data. Amgen's stock price may be volatile and may be affected by a number of events. Amgen's business and operations may be negatively affected by the failure, or perceived failure, of achieving its environmental, social and governance objectives. The effects of global climate change and related natural disasters could negatively affect Amgen's business and operations. Global economic conditions may magnify certain risks that affect Amgen's business. Amgen's business performance could affect or limit the ability of the Amgen Board of Directors to declare a dividend or its ability to pay a dividend or repurchase its common stock. Amgen may not be able to access the capital and credit markets on terms that are favorable to it, or at all. Any scientific information discussed in this news release relating to new indications for Amgen's products is preliminary and investigative and is not part of the labeling approved by the U.S. Food and Drug Administration for the products. The products are not approved for the investigational use(s) discussed in this news release, and no conclusions can or should be drawn regarding the safety or effectiveness of the products for these uses. CONTACT: Amgen, Thousand Oaks Elissa Snook , 609-251-1407 (media) Justin Claeys , 805-313-9775 (investors) References View original content to download multimedia: https://www.prnewswire.com/news-releases/blincyto-blinatumomab-added-to-chemotherapy-significantly-improves-survival-in-newly-diagnosed-pediatric-patients-with-b-cell-precursor-acute-lymphoblastic-leukemia-b-all-302325381.html SOURCE Amgen
2024 was the year robotaxis proved they are here to stay
FormFactor, Inc. (NASDAQ:FORM) Receives Consensus Recommendation of “Moderate Buy” from Analysts